Reduction of r-hirudin induced bleeding in pigs by the administration of von Willebrand factor

Platelets

Volumn 7, Issue 5-6, 1996, Pages 283-290

  Dickneite, G ^a,c   Friesen, H J ^b   Kumpe, G ^a   Reers, M ^b  

^a Research Laboratories of Centeon Pharma GmbH   (Germany)

^b Behringwerke AG   (Germany)

^c Centeon Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 8 CONCENTRATE; HIRUDIN; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BLOOD LEVEL; CONTROLLED STUDY; EAR; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SKIN; SWINE; THROMBOCYTE ADHESION; VASCULAR ENDOTHELIUM;

ANIMALIA; STAPHYLOCOCCUS PHAGE 187; SUS SCROFA;

EID: 0030463933     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.3109/09537109609023590     Document Type: Article

References (23)

1. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263: 10451-5.
2. Lyons SE, Ginsburg E. Molecular and cellular biology of von Willebrand Factor. Trends Cardiovasc Med 1994; 4: 34-39.
3. Obberghen-Schilling E van, Pouysségur J. α-Thrombin receptors and growth signaling. Semin Thromb Hemost 1993; 19: 378-85.
4. Marder VJ. Thrombolytic therapy: overview of results in major vascular occlusions. Thromb Haemost 1995; 74: 101-5.
5. Verstraete M, Lijnen HR, Collen D. Thrombolytic agents in development. Drugs 1995; 50: 29-42.
6. Dechend R. Gulba DC, Hauck S, Dietz R. The problem of reocclusion and restenosis - clinical aspects. Fibrinolysis 1995; 9: 48-52.
7. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial on intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction. Lancet 1988; 8607: 349-60.
8. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Müller HS, Braunwald E. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23: 993-1003.
9. Markwardt F. Die Isolierung und chemische Charakterisierung des Hirudins. Hoppe-Seyler's Z Physiol Chem 1957; 308: 147-56.
10. Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25: 4622-8.
11. Markwardt F. The comeback of hirudin as an antithrombotic agent. Semin Thromb Haemost 1991; 17: 79-82.
12. Walenga JM, Pifarre R, Fareed J. Recombinant hirudin as an antithrombotic agent. Drugs Future 1990; 15: 267-80.
13. Badimon L, Merino A, Badimon J, Chesebro JH, Fuster V. Hirudin and other Thrombin inhibitors. Teratogen Carcinogen Mutagen 1991; 1: 261-7.
14. Dodt J. Anticoagulatory substances of bloodsucking animals: from hirudin to hirudin mimetics. Angew Chem Int Ed Engl 1995; 34: 867-80.
15. Molhoek GP, Laarman GJ, Lok DJA, Luz CM, Kingma JH, Bos AA van den, Zijnen P, Bosma AH, Hertzberger DP, Takens LH. Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HITSK). Eur Heart J 1995; 16: 33-7.
16. Zeymer U, Essen R von, Tebbe U, Michels H-R, Jessel A, Vogt A, Roth M, Appel K-F, Neuhaus K-L. Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study. Eur Heart J 1995; 16: 22-7.
17. Serruys PW, Herrman J-PR, Simon R, Rutsch W, Bode C, Laarman G-J, Deckers JW. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995; 333: 757-63.
18. Fox KAA. r-Hirudin in unstable angina pectoris. Eur Heart J 1995; 16: 28-32.
19. Eriksson BI, Kälebo P, Ekman S, Lindbratt S, Kerry R. Close P. Direct thrombin inhibition with rec.-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Hemost 1994; 72: 227-37.
20. Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995; 50: 20-5.
21. Antman EM, TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-30.
22. Neuhaus KL, Essen R von, Tebbe U, Jessel A, Heinrichs H, Mäurer W, Döling W, Harmjanz D, Kötier V, Kalhammer E, Simon H, Goracek T. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation 1994; 90: 1638-42.
23. Topol E, GUSTO Ha Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7.